Display Settings:

Format

Send to:

Choose Destination

    J Infect Dis. 2001 Jun 15;183(12):1775-80. Epub 2001 May 17.

    An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.

    Yang HH, Kilgore PE, Yang LH, Park JK, Pan YF, Kim Y, Lee YJ, Xu ZY, Clemens JD.

    Guangxi Health and Anti-Epidemic Center, Guangxi Zhuang Autonomous Region, People's Republic of China.

    Comment in:

    To evaluate the effectiveness of Vi polysaccharide vaccine (Vi vaccine) in preventing typhoid fever, an analysis was done of an outbreak of typhoid fever among students attending a middle school in the People's Republic of China, where Vi vaccine is licensed for use. Vi vaccine effectiveness was analyzed by using Cox proportional hazards modeling to account for the time-dependent nature of vaccination and illness status during the outbreak. Among 1260 students who had been immunized before the outbreak, receipt of Vi vaccine was associated with 73% (95% confidence interval [CI], 32%-89%) protection. Among the additional 441 students immunized during the outbreak, receipt of Vi vaccine was associated with 71% (95% CI, -9% to 92%) protection. These results provide the first evidence about the effectiveness of Vi vaccine when deployed routinely in a typhoid-endemic area and support the use of Vi vaccine as a public health tool to control typhoid fever.

    PMID: 11372030 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Typhoid Vaccine (Typhim Vi®, Vivotif Berna®)

      Typhoid (typhoid fever) is a serious disease. It is caused by bacteria calledSalmonella Typhi. Typhoid causes a high fever, weakness, stomach pains, headache, loss of appetite, and sometimes a rash. If it is not treated,...